Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa

Hormones and Behavior

Volumn 50, Issue 2, 2006, Pages 261-265

  Tanaka, Muneki ^a,c   Nakahara, Toshihiro ^a   Muranaga, Tetsuro ^a   Kojima, Shinya ^c   Yasuhara, Daisuke ^c   Ueno, Hiroaki ^b   Nakazato, Masamitsu ^b   Inui, Akio ^a,c  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Bulimia nervosa; Cardiac vagal tone; Ghrelin; Leptin

Indexed keywords

GHRELIN; LEPTIN; PAROXETINE;

ADULT; ARTICLE; BEHAVIOR; BINGE EATING DISORDER; BODY FAT; BODY MASS; BULIMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DISEASE ASSOCIATION; FEMALE; HEART FUNCTION; HUMAN; OUTPATIENT; PRIORITY JOURNAL; SEX RATIO; VAGUS TONE; VOMITING;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY COMPOSITION; BODY MASS INDEX; BULIMIA; COGNITIVE THERAPY; FEMALE; HEART; HUMANS; LEPTIN; PAROXETINE; PEPTIDE HORMONES; PSYCHIATRIC STATUS RATING SCALES; VAGUS NERVE;

EID: 33745913642     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2006.03.009     Document Type: Article

References (47)

1. Agras W.S., Rossiter E.M., Arnow B., Schneider J.A., Telch C.F., Raeburn S.D., Bruce B., Perl M., and Koran L.M. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am. J. Psychiatry 149 (1992) 82-87
2. Akselrod S., Gordon D., Ubel F.A., Shannon D.C., Berger A.C., and Cohen R.J. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213 (1981) 220-222
3. Andrews P.L., Davis C.J., Bingham S., Davidson H.I., Hawthorn J., and Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can. J. Physiol. Pharm. 68 (1990) 325-345
4. Asakawa A., Inui A., Kaga T., Yuzuriha H., Nagata T., Ueno N., Makino S., Fujimiya M., Niijima A., Fujino M.A., and Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120 (2001) 337-345
5. Bigger Jr. J.T., Fleiss J.L., Steinman R.C., Rolnitzky L.M., Schneider W.J., and Stein P.K. RR variability in healthy, middle-aged persons compared with patients with chronic coronary heart disease or recent acute myocardial infarction. Circulation 91 (1995) 1936-1943
6. Bolanowski M., and Nilsson B.E. Assessment of human body composition using dual-energy X-ray absorptiometry and bioelectrical impedance analysis. Med. Sci. Monit. 7 (2001) 1029-1033
7. Brewerton T.D., Lesem M.D., Kennedy A., and Garvey W.T. Reduced plasma leptin concentrations in bulimia nervosa. Psychoneuroendocrinology 25 (2000) 649-658
8. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
9. Fairburn C.G., Marcus M.D., and Wilson G.T. Cognitive-behavioral therapy for binge eating and bulimia nervosa: a comprehensive treatment manual. In: Fairburn C.G., and Wilson G.T. (Eds). Binge Eating: Nature, Assessment and Treatment (1993), The Guilford Press, New York 361-405
10. Fan P. Inhibition of a 5-HT3 receptor-mediated current by the selective serotonin uptake inhibitor, fluoxetine. Neurosci. Lett. 173 (1994) 210-212
11. Fan P. Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine. Neuroscience 62 (1994) 515-522
12. Faris P.L., Kim S.W., Meller W.H., Goodale R.L., Oakman S.A., Hofbauer R.D., Marshall A.M., Daughters R.S., Banerjee-Stevens D., Eckert E.D., and Hartman B.K. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 355 (2000) 792-797
13. Fassino S., Daga G.A., Mondelli V., Pierò A., Broglio F., Picu A., Giordano R., Baldi M., Arvat E., Ghigo E., and Gianotti L. Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa. Psychoneuroendocrinology 30 (2005) 534-540
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders-Patient edition (SCID I/P, Version 2.0). Biometric Research (1995), New York State Psychiatric Institute, New York
15. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. Arch. Gen. Psychiatry 49 (1992) 139-147
16. Goldbloom D.S., and Olmsted M.P. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am. J. Psychiatry 150 (1993) 770-774
17. Goldstein D.J., Wilson M.G., Thompson V.L., Potvin J.H., Rampey Jr. A.H., and Fluoxetine Bulimia Nervosa Research Group. Long-term fluoxetine treatment of bulimia nervosa. Br. J. Psychiatry 166 (1995) 660-666
18. Hayano J., Sakakibara Y., Yamada M., Ohte N., Fujinami T., Yokoyama K., Watanabe Y., and Takata K. Decreased magnitude of heart rate spectral components in coronary artery disease. Its relation to angiographic severity. Circulation 81 (1990) 1217-1224
19. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat. Rev., Neurosci. 2 (2001) 551-560
20. Jimerson D.C., Lesem M.D., Kaye W.H., Hegg A.P., and Brewerton T.D. Eating disorders and depression: is there a serotonin connection. Biol. Psychiatry 28 (1990) 443-454
21. Jimerson D.C., Mantzoros C., Wolfe B.E., and Metzger E.D. Decreased serum leptin in bulimia nervosa. J. Clin. Endocrinol. Metab. 85 (2000) 4511-4514
22. Judge R., Parry M.G., Quail D., and Jacobson J.G. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol. 17 (2002) 217-225
23. Kennedy S.H., and Heslegrave R.J. Cardiac regulation in bulimia nervosa. J. Psychiatr. Res. 23 (1989) 267-273
24. Kennett G.A., Lightowler S., de Biasi V., Stevens N.C., Wood M.D., Tulloch I.F., and Blackburn T.P. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33 (1994) 1581-1588
25. Knox A.P., Strominger N.L., Battles A.H., and Carpenter D.O. The central connections of the vagus nerve in the ferret. Brain Res. Bull. 33 (1994) 49-63
26. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
27. Kojima S., Nakahara T., Nagai N., Muranaga T., Tanaka M., Yasuhara D., Masuda A., Date Y., Ueno H., Nakazato M., and Naruo T. Altered ghrelin and peptide YY responses to meals in bulimia nervosa. Clin. Endocrinol. 62 (2005) 74-78
28. Masuda Y., Tanaka T., Inomata N., Ohnuma N., Tanaka S., Itoh Z., Hosoda H., Kojima M., and Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276 (2000) 905-908
29. Metzger E.D., Levine J.M., McArdle C.R., Wolfe B.E., and Jimerson D.C. Salivary gland enlargement and elevated serum amylase in bulimia nervosa. Biol. Psychiatry 45 (1999) 1520-1522
30. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
31. Pagani M., Lombardi F., Guzzetti S., Rimoldi O., Furlan R., Pizzinelli P., Sandrone G., Malfatto G., Dell'Orto S., Piccaluga E., Turiel M., Baselli G., Cerutti S., and Malliani A. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ. Res. 59 (1986) 178-193
32. Porges S.W. Orienting in a defensive world: mammalian modifications of our evolutionary heritage. A polyvagal theory. Psychophysiology 32 (1995) 301-318
33. Rissanen A., Naukkarinen H., Virkkunen M., Rawlings R.R., and Linnoila M. Fluoxetine normalizes increased cardiac vagal tone in bulimia nervosa. J. Clin. Psychopharmacol. 18 (1998) 26-32
34. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., Nozoe S., Hosoda H., Kangawa K., and Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab. 87 (2002) 240-244
35. Shintani M., Ogawa Y., Ebihara K., Aizawa-Abe M., Miyanaga F., Takaya K., Hayashi T., Inoue G., Hosoda K., Kojima M., Kangawa K., and Nakao K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50 (2001) 227-232
36. Steiger H., Young S.N., Kin N.M., Koerner N., Israel M., Lageix P., and Paris J. Implications of impulsive and affective symptoms for serotonin function in bulimia nervosa. Psychol. Med. 31 (2001) 85-95
37. Takaya K., Ariyasu H., Kanamoto N., Iwakura H., Yoshimoto A., Harada M., Mori K., Komatsu Y., Usui T., Shimatsu A., Ogawa Y., Hosoda K., Akamizu T., Kojima M., Kangawa K., and Nakao K. Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85 (2000) 4908-4911
38. Tanaka M., Naruo T., Muranaga T., Yasuhara D., Shiiya T., Nakazato M., Matsukura S., and Nozoe S. Increased fasting plasma ghrelin levels in patients with bulimia nervosa. Eur. J. Endocrinol. 146 (2002) R1-R3
39. Tanaka M., Naruo T., Nagai N., Kuroki N., Shiiya T., Nakazato M., Matsukura S., and Nozoe S. Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders. J. Psychiatr. Res. 37 (2003) 17-22
40. Tanaka M., Naruo T., Yasuhara D., Tatebe Y., Nagai N., Shiiya T., Nakazato M., Matsukura S., and Nozoe S. Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology 28 (2003) 829-835
41. Tanaka M., Tatebe Y., Nakahara T., Yasuhara D., Sagiyama K., Muranaga T., Ueno H., Nakazato M., Nozoe S., and Naruo T. Eating pattern and the effect of oral glucose on ghrelin and insulin secretion in patients with anorexia nervosa. Clin. Endocrinol. 59 (2003) 574-579
42. Tanaka M., Nakahara T., Kojima S., Nakano T., Muranaga T., Nagai N., Ueno H., Nakazato M., Nozoe S., and Naruo T. Effect of nutritional rehabilitation on circulating ghrelin and growth hormone levels in patients with anorexia nervosa. Regul. Pept. 122 (2004) 163-168
43. Tschöp M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
44. Vickers S.P., Easton N., Webster L.J., Wyatt A., Bickerdike M.J., Dourish C.T., and Kennett G.A. Oral administration of the 5-HT2Creceptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacologia 167 (2003) 274-280
45. Walsh B.T., Wilson G.T., Loeb K.L., Devlin M.J., Pike K.M., Roose S.P., Fleiss J., and Waternaux C. Medication and psychotherapy in the treatment of bulimia nervosa. Am. J. Psychiatry 154 (1997) 523-531
46. Wolfe B.E., Metzger E.D., Levine J.M., and Jimerson D.C. Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study. Int. J. Eat. Disord. 30 (2001) 288-293
47. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A., and Bloom S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 5992